Abstract
As stated early in part I of the article, the focus of this article is for moderately COVID-19 affected ongoing trials where no formal interim analysis is planned. This requires a comprehensive assessment of each attribute of an estimand affected by unplanned trial modifications due to COVID-19. In addition, a formal process for adaptive statistical analysis planning, as described by Liu and Chi (2010a) and restated below, is also required.
| Original language | American English |
|---|---|
| Journal | |
| State | Published - Apr 15 2020 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Disciplines
- Biostatistics
- Environmental Public Health
- Epidemiology
- Public Health
Fingerprint
Dive into the research topics of 'Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands (Part III)'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver